HIV broadly neutralizing antibodies (bnAbs) can suppress viremia and protect against HIV
infection. However, their elicitation is made difficult by low frequencies of appropriate …

INTRODUCTION A major goal of HIV-1 vaccine development is the design of immunogens
that induce broadly neutralizing antibodies (bnAbs). However, vaccination of humans has …

Development of strategies for induction of HIV-1 broadly neutralizing antibodies (bnAbs) by
vaccines is a priority. Determining the steps of bnAb induction in HIV-1-infected individuals …

Failure of immunization with the HIV-1 envelope to induce broadly neutralizing antibodies
against conserved epitopes is a major barrier to producing a preventive HIV-1 vaccine …

A major goal of HIV-1 vaccine development is the induction of broadly neutralizing
antibodies (bnAbs). Although success has been achieved in initiating bnAb B cell lineages …

Transplantation of B cells engineered ex vivo to secrete broadly neutralizing antibodies
(bNAbs) has shown efficacy in disease models. However, clinical translation of this …

INTRODUCTION HIV newly infects 1.8 million people each year, making development of an
HIV vaccine a global health priority. Nearly all licensed vaccines protect by inducing …

Introduction A primary focus of HIV‐1 vaccine development is the activation of B cell
receptors for naïve or precursor broadly neutralizing antibodies (bnAbs), followed by …

Low affinity is common for germline B cell receptors (BCR) seeding development of broadly
neutralizing antibodies (bnAbs) that engage hypervariable viruses, including HIV. Antibody …

After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …